Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.190
-0.260 (-17.93%)
Apr 29, 2026, 11:48 AM EDT - Market open

Rein Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-49.87-62.88-15.73-27.33-26.16
Upgrade
Depreciation & Amortization
00.060.120.170.12
Upgrade
Loss (Gain) From Sale of Assets
---0.04--0.07
Upgrade
Asset Writedown & Restructuring Costs
28.737---
Upgrade
Loss (Gain) From Sale of Investments
--0.03-0.210.24
Upgrade
Stock-Based Compensation
2.221.121.192.082.26
Upgrade
Other Operating Activities
0.45----0.39
Upgrade
Change in Accounts Payable
3.07-0.28-4.980.51-0.39
Upgrade
Change in Other Net Operating Assets
-3.224.25-0.4-0.090.63
Upgrade
Operating Cash Flow
-19.36-22.29-19.81-24.87-23.75
Upgrade
Capital Expenditures
-----0.16
Upgrade
Sale of Property, Plant & Equipment
--0.04-0.07
Upgrade
Cash Acquisitions
---0.1--
Upgrade
Investment in Securities
--16.2526.46-35.83
Upgrade
Investing Cash Flow
--16.226.46-35.92
Upgrade
Long-Term Debt Issued
--15.79--
Upgrade
Net Debt Issued (Repaid)
--15.79--
Upgrade
Issuance of Common Stock
3.4410.79--59.16
Upgrade
Other Financing Activities
6.327.03---3.51
Upgrade
Financing Cash Flow
9.7617.8215.79-55.66
Upgrade
Foreign Exchange Rate Adjustments
-0.04--0.06--
Upgrade
Net Cash Flow
-9.65-4.4712.121.59-4.01
Upgrade
Free Cash Flow
-19.36-22.29-19.81-24.87-23.91
Upgrade
Free Cash Flow Per Share
-0.76-1.24-4.31-5.48-5.38
Upgrade
Levered Free Cash Flow
-11.37-14.82-7.62-14.48-13.5
Upgrade
Unlevered Free Cash Flow
-11.37-14.82-7.62-14.48-13.5
Upgrade
Change in Working Capital
-0.872.41-5.380.420.24
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.